By Josh Beckerman
Reata Pharmaceuticals Inc. shares were recently down 30% to $38 after hours after the company received a negative opinion from a Food and Drug Administration advisory committee for its new drug application for bardoxolone methyl.
Reata shares were halted all day Wednesday.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
12-08-21 1910ET